Vanda Pharmaceuticals Q2 revenue up 4%

Vanda Pharmaceuticals

31/07/2025 12:45

Overview

Vanda Q2 revenue rises 4% yr/yr to $52.6 mln, no analyst estimate provided

Net loss widens to $27.2 mln in Q2 from $4.5 mln in Q2 2024

Fanapt revenue grows 27% yr/yr, driven by sales efforts and brand campaign

Outlook

Vanda expects 2025 revenue between $210 mln and $250 mln

Company forecasts year-end 2025 cash between $280 mln and $320 mln

Vanda anticipates continued Fanapt revenue growth in coming quarters

Company expects significant regulatory milestones in coming months

Result Drivers

FANAPT SALES GROWTH - Driven by expanded sales efforts and direct-to-consumer brand awareness campaign

REGULATORY MILESTONES - Significant upcoming milestones expected to strengthen commercial portfolio

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$52.59 bln
Q2 Adjusted EPS
-$0.46
Q2 EPS
-$0.46
Q2 Net Income
-$27.21 mln
Q2 Basic EPS
-$0.46
Q2 Operating Expenses
$91.09 mln
Q2 Operating Income
-$38.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc is $13.00, about 64.1% above its July 30 closing price of $4.67

Press Release: ID:nPn50CMm9a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)